Ultima-AOD9604 5mg

MANUFACTURER Ultima Pharmaceuticals - USA
WAREHOUSE USA Warehouse 5
SUBSTANCE AOD 9604 - Anti-Obesity Drug

For added security, products are shipped without branding.

AOD 9604 is a groundbreaking derivative of Growth Hormone, crafted from a 191 amino acid peptide. This innovative peptide is derived from the final 15 amino acids (positions 176-191) of the Growth Hormone molecule, known as GH Frag 176-191 or AOD 9604.

Renowned as one of the most potent peptides for weight management, AOD 9604 not only aids in fat loss but also boosts metabolism, providing a multitude of benefits.

Target Gland: Pituitary Gland

• Significantly reduces body fat
• Specifically targets the release of fat from obese cells, sparing lean tissue
• Mirrors the natural fat metabolism regulation of growth hormone
• Maintains normal blood sugar levels with no impact on growth
• Stimulates the process of lipolysis
• Inhibits lipogenesis, preventing the conversion of non-fatty foods into stored fat
• Exhibits beneficial properties for cartilage repair and regeneration, especially when paired with peptide BPC 157.

Mechanism of Action:

AOD-9604, also known as Tyr-hGH Frag 176-191, effectively promotes fat burning without increasing appetite. It operates independently of hGH receptors, showing no adverse effects on blood sugar or tissue growth (Heffernan 2001, Ng 2000). Research across a variety of species, including rodents, pigs, dogs, and humans, illustrates that AOD-9604 enhances fat oxidation and facilitates the release of fat from obese cells while curbing new fat accumulation. Particularly effective in targeting abdominal fat, AOD-9604 is a powerful ally in weight loss.

If fat loss is your primary goal, it's best to avoid GHRP products (like GHRP-6 or GHRP-2), as these can lead to increased hunger and cortisol levels. In contrast, AOD-9604 does not trigger appetite spikes or cortisol surges.

AOD 9604 Research Insights:

First developed in the 1990s by Professor Frank Ng at Monash University in Australia, AOD-9604 was designed to harness the fat-burning advantages of human growth hormone (HGH) without stimulating muscle growth.

Recent studies have uncovered additional regenerative properties associated with AOD 9604, prompting ongoing clinical trials to explore its potential benefits in treating osteoarthritis, hypercholesterolemia, and aiding in the repair of bone and cartilage.

Oral glucose tolerance tests have indicated that, unlike HGH, AOD 9604 does not negatively affect carbohydrate metabolism. Furthermore, no anti-AOD 9604 antibodies have been detected in patients, and studies report no severe adverse effects or withdrawal symptoms linked to AOD 9604 usage.

Conclusion:

AOD 9604 boasts an impressive safety and tolerability profile, akin to that of a placebo, and does not carry the adverse side effects typical of full-length hGH treatments. With a strong safety record, AOD 9604 has recently achieved Human GRAS status in the USA.